List of Excipients in Branded Drug INPEFA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lexicon Pharmaceuticals Inc	INPEFA	sotagliflozin	70183-220	CROSCARMELLOSE SODIUM	2030-10-07
Lexicon Pharmaceuticals Inc	INPEFA	sotagliflozin	70183-220	FD&C BLUE NO. 2	2030-10-07
Lexicon Pharmaceuticals Inc	INPEFA	sotagliflozin	70183-220	MAGNESIUM STEARATE	2030-10-07
Lexicon Pharmaceuticals Inc	INPEFA	sotagliflozin	70183-220	MICROCRYSTALLINE CELLULOSE 102	2030-10-07
Lexicon Pharmaceuticals Inc	INPEFA	sotagliflozin	70183-220	MICROCRYSTALLINE CELLULOSE 200	2030-10-07
Lexicon Pharmaceuticals Inc	INPEFA	sotagliflozin	70183-220	POLYETHYLENE GLYCOL	2030-10-07

INPEFA Excipient Strategy and Commercial Opportunities: Sotagliflozin Formulation, Generic Risk, and Market Outlook

Last updated: August 21, 2026

INPEFA is the brand name for sotagliflozin, an oral sodium-glucose cotransporter 1 and 2 inhibitor developed by Lexicon Pharmaceuticals. The product is marketed as immediate-release 200 mg and 400 mg tablets. Its excipient platform uses conventional, widely available tablet ingredients, which limits formulation differentiation but creates opportunities for generic manufacturers, regional contract development and manufacturing organizations, and reformulated combination products.

The principal commercial constraint is competition from established SGLT2 inhibitors, including Jardiance (empagliflozin) and Farxiga (dapagliflozin). INPEFA’s differentiated value is its dual SGLT1/SGLT2 mechanism and cardiovascular, heart-failure, and chronic-kidney-disease positioning rather than a difficult-to-copy delivery system.

What is INPEFA and which excipients are used in the tablets?

INPEFA contains sotagliflozin and is supplied as immediate-release oral tablets in 200 mg and 400 mg strengths. The FDA prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation role	Commercial assessment
Microcrystalline cellulose	Diluent and tablet-bulk agent	Commodity-grade supply; broad generic availability
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup
Povidone	Binder	Common in wet or dry granulation systems
Magnesium stearate	Lubricant	Standard tableting lubricant
Sodium lauryl sulfate	Wetting and dissolution aid	May improve hydrophobic drug wetting
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend uniformity

The excipient list is consistent with a conventional immediate-release tablet. No publicly identified lipid-based system, osmotic delivery system, enteric coating, depot technology, or complex multiparticulate architecture differentiates INPEFA from standard oral solid-dose products (U.S. Food and Drug Administration [FDA], 2023).

Sotagliflozin’s formulation strategy appears directed toward manufacturing reliability, acceptable dissolution, and dose flexibility rather than lifecycle protection through delivery technology.

How does the INPEFA formulation work from a manufacturing perspective?

The formulation has several manufacturing advantages.

Conventional tableting process

Microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, sodium lauryl sulfate, and colloidal silicon dioxide are widely used in immediate-release tablets. Manufacturers with standard high-shear granulation, roller compaction, or direct-compression capabilities could potentially develop a comparable dosage form without specialized equipment.

The main development variables are likely to include:

• Drug loading at the 200 mg and 400 mg strengths
• Blend uniformity
• Lubrication time and magnesium stearate concentration
• Disintegration performance
• Dissolution across physiologic pH conditions
• Moisture control
• Tablet hardness and friability
• Stability under commercial packaging conditions

Role of sodium lauryl sulfate

Sodium lauryl sulfate is commercially important because it can improve wetting of poorly water-soluble active pharmaceutical ingredients. Its use may support dissolution consistency, but it also creates development considerations involving taste, gastrointestinal tolerability, particle-size distribution, and interaction with other formulation components.

A generic developer would need to match dissolution performance without assuming that the same concentration or grade is necessary. Alternative wetting agents could create a lower-risk formulation if they preserve bioequivalence and stability.

Role of superdisintegrant and lubricant balance

Croscarmellose sodium supports rapid tablet disintegration. Excessive magnesium stearate or extended lubrication can reduce tablet wettability and slow dissolution. This makes the lubricant-disintegrant balance a practical development issue, even though neither excipient is likely to create meaningful intellectual-property protection by itself.

Supply-chain profile

The listed excipients are available from multiple global suppliers. They do not appear to create a material single-source barrier. Commercial opportunities therefore are more likely to arise from:

• Excipient-grade optimization
• Low-nitrite or low-peroxide grades
• Regional supply qualification
• Cost reduction
• Continuous manufacturing
• Improved stability packaging
• Integrated active pharmaceutical ingredient and finished-dose supply

What formulation patents protect INPEFA?

The commercial protection of INPEFA is expected to rely primarily on sotagliflozin and therapeutic-use patents rather than on a highly differentiated excipient system.

The public FDA prescribing information identifies the approved strength and dosage form but does not provide a complete commercial analysis of every potentially enforceable patent claim. FDA Orange Book listings, Lexicon patent disclosures, and relevant patent-family records must be reviewed separately for current patent numbers, terminal disclaimers, pediatric extensions, and litigation status (FDA, 2024; Lexicon Pharmaceuticals, 2024).

For formulation competitors, the principal legal questions are:

1. Whether a patent claims sotagliflozin as a chemical entity.
2. Whether a patent claims a specific crystalline or polymorphic form.
3. Whether a patent claims the approved immediate-release composition.
4. Whether a patent claims dosing in heart failure or chronic kidney disease.
5. Whether the proposed generic label would induce infringement of a method-of-use claim.
6. Whether the generic formulation can use different excipients while meeting FDA bioequivalence requirements.

A formulation using different binders, fillers, lubricants, or wetting agents may avoid a narrow composition claim. It would not necessarily avoid claims directed to the active ingredient, a salt or solid form, or a method of treatment.

When does INPEFA lose regulatory exclusivity?

INPEFA received FDA approval on May 26, 2023. Because sotagliflozin was approved as a new molecular entity, the product is generally associated with five years of new chemical entity exclusivity, subject to the FDA’s definitive Orange Book records and applicable statutory rules. The expected five-year period would run to approximately May 26, 2028. An ANDA containing a Paragraph IV certification may generally be submitted during the fourth year, while approval may be delayed until the exclusivity period ends unless the statutory conditions for earlier approval are satisfied (FDA, 2023; FDA, 2024).

Regulatory exclusivity and patent protection are separate. A patent may expire before or after the NCE exclusivity period. Patent-term adjustment, patent-term extension, pediatric exclusivity, and litigation outcomes can change the effective generic-entry date.

Milestone	Date or status
FDA approval of INPEFA	May 26, 2023
New chemical entity exclusivity	Expected to run to approximately May 26, 2028
Earliest typical fourth-year Paragraph IV filing window	Approximately May 26, 2027
Generic approval absent blocking patents or litigation	Dependent on Orange Book and exclusivity status
Biosimilar pathway	Not applicable; sotagliflozin is a small molecule

What is the Orange Book status of INPEFA?

INPEFA is regulated as a small-molecule drug and is listed through FDA’s Orange Book framework rather than the biosimilar pathway. Orange Book analysis should focus on:

• Listed patents covering sotagliflozin
• Use codes for cardiovascular, heart-failure, kidney-disease, or diabetes indications
• Patent expiration dates
• Whether any patents qualify for Paragraph IV challenges
• Whether the approved label contains protected uses that a generic applicant can carve out
• Any 30-month litigation stay triggered by a patent-infringement action

A generic applicant could pursue a full-label ANDA, a section viii statement for unpatented uses, or a Paragraph IV strategy. The viability of a carve-out depends on the scope of the listed method-of-use claims and whether the remaining label still supports a commercially meaningful market.

Which companies are challenging INPEFA patents?

No major public Paragraph IV litigation profile is established in the information reviewed here. INPEFA’s relatively recent launch and modest commercial scale may reduce the immediate incentive for first-wave generic challenges compared with high-revenue drugs.

Potential challengers would most likely include:

• Large generic companies with cardiovascular portfolios
• Indian manufacturers with SGLT2 development capabilities
• Contract development organizations seeking an ANDA partner
• Companies pursuing regional launches after U.S. exclusivity loss

A Paragraph IV challenge becomes more attractive if INPEFA demonstrates durable adoption in heart failure or chronic kidney disease, or if the product obtains a broader label. The commercial value of a challenge depends on whether the challenger can enter before the relevant patents expire and whether the generic can access the principal reimbursed uses.

How strong is the INPEFA patent estate?

The patent estate is likely stronger around the active ingredient and therapeutic use than around excipient selection.

Protection category	Relative strength	Generic implication
Sotagliflozin composition of matter	Potentially high	May delay active-ingredient entry
Solid form or polymorph	Case-specific	May require alternative form or non-infringing process
Immediate-release tablet composition	Moderate to low if narrowly claimed	Excipient substitution may be possible
Cardiovascular method of use	Potentially material	Could limit full-label promotion
Chronic kidney disease method of use	Potentially material	Carve-out analysis required
Manufacturing process	Variable	API suppliers must assess process claims
Excipient combination	Likely limited	Conventional ingredients are readily substituted

The absence of a complex delivery platform reduces formulation barriers. It also limits the ability to use excipient patents as a long-term barrier to generic entry.

What generic entry risks exist for INPEFA?

INPEFA faces five principal generic-entry risks.

1. Conventional dosage form

Immediate-release tablets are among the most reproducible oral dosage forms. A competitor does not need specialized manufacturing technology to develop a bioequivalent product.

2. Broad excipient substitutability

The formulation can potentially be redesigned around alternative fillers, binders, disintegrants, lubricants, and surfactants. This reduces the likelihood that a narrow excipient claim will block entry.

3. SGLT2 class competition

Jardiance and Farxiga have established prescriber familiarity, payer coverage, and clinical evidence. A generic sotagliflozin product would enter a class with strong branded and generic substitution dynamics.

4. Label-carve-out constraints

If major commercial uses are covered by method-of-use patents, a generic applicant may face a choice between a narrow label and Paragraph IV litigation. A narrow label can reduce market access even when technical bioequivalence is straightforward.

5. Limited scale before loss of exclusivity

A product with limited pre-expiry sales may not attract multiple generic applicants. That can reduce immediate price erosion but also weakens the expected value of the branded franchise and discourages investment in specialized formulation improvements.

What commercial opportunities exist for INPEFA excipients?

The most credible excipient-related opportunities are incremental rather than platform-based.

Low-cost generic tablets

Manufacturers can pursue a standard immediate-release product using widely available excipients. Cost advantages may come from:

• Direct compression
• Reduced manufacturing steps
• High-throughput tablet presses
• Regional excipient sourcing
• Lower-cost blister or bottle packaging
• Dual-strength production on a shared platform

Dissolution-optimized formulations

Sotagliflozin formulations can be screened with alternative wetting agents, particle-size distributions, and disintegration systems. A developer may obtain better dissolution robustness without creating a new dosage form.

This opportunity is most relevant if the reference product has dissolution sensitivity related to API particle size, lubrication, or surfactant concentration.

Fixed-dose combinations

A fixed-dose combination with another cardiovascular, kidney, or diabetes medicine could create a stronger lifecycle opportunity than an excipient-only reformulation. Candidate combinations would require assessment of dose timing, renal function, pharmacokinetic compatibility, stability, and regulatory labeling.

Potential categories include:

• Renin-angiotensin system agents
• Mineralocorticoid receptor antagonists
• Diuretics
• Antihypertensive agents
• Other glucose-lowering medicines

A combination product could improve adherence but would face a higher development burden than a conventional generic tablet.

Alternative dosage forms

A smaller tablet, orally disintegrating tablet, or sprinkle formulation could target patients with swallowing difficulty. The commercial value would depend on whether the product maintains sotagliflozin exposure, preserves the before-meal dosing instruction, and improves adherence sufficiently to justify a new regulatory program.

Pediatric expansion is less immediately attractive because the principal approved populations are adults with heart failure or chronic kidney disease and adults with type 2 diabetes and associated cardiovascular or renal risk.

Contract manufacturing and regional licensing

Lexicon’s commercial strategy creates opportunities for regional partners to supply or distribute sotagliflozin outside the core U.S. market. The strongest candidates are manufacturers with:

• Existing cardiovascular sales infrastructure
• SGLT2 regulatory experience
• Local reimbursement access
• Finished-dose capacity
• Ability to support post-approval studies

The excipient system does not create a meaningful barrier to regional manufacturing. The principal barriers are API rights, regulatory approvals, clinical data, trademarks, and market access.

How does INPEFA compare with Jardiance and Farxiga?

Attribute	INPEFA	Jardiance	Farxiga
Active ingredient	Sotagliflozin	Empagliflozin	Dapagliflozin
Mechanism	SGLT1/SGLT2 inhibition	Primarily SGLT2 inhibition	Primarily SGLT2 inhibition
Dosage form	Immediate-release tablet	Immediate-release tablet	Immediate-release tablet
Excipient differentiation	Limited public evidence	Limited public evidence	Limited public evidence
Commercial position	Newer, smaller franchise	Established cardiovascular and diabetes franchise	Established cardiovascular, kidney, and diabetes franchise
Generic risk	Medium to high after core protection	Depends on patent and regulatory status	Depends on patent and regulatory status
Biosimilar risk	Not applicable	Not applicable	Not applicable
Main competitive advantage	Dual transporter mechanism and target-label positioning	Scale, clinical adoption, and established reimbursement	Scale, clinical evidence, and broad disease positioning

INPEFA’s formulation is not the primary source of differentiation against these products. Clinical outcomes, guideline incorporation, reimbursement, and physician confidence will determine market share.

What litigation and settlement issues could affect INPEFA?

The key litigation triggers would be:

• A Paragraph IV certification against an Orange Book-listed patent
• An infringement action within 45 days of notice
• A statutory 30-month stay
• A settlement permitting an agreed generic launch date
• A patent-term extension or pediatric exclusivity award
• Litigation over a solid form, manufacturing process, or method of treatment

No settlement should be assumed without a public agreement or court filing. A settlement could create an earlier generic-entry date than the nominal patent expiration, but its business effect would depend on the number of authorized or licensed entrants and any restrictions on formulation, indication, or launch timing.

Key Takeaways

• INPEFA is a conventional immediate-release sotagliflozin tablet in 200 mg and 400 mg strengths.
• Its listed excipients include microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, sodium lauryl sulfate, and colloidal silicon dioxide.
• The excipient platform is commercially reproducible and unlikely to create a major generic barrier.
• The strongest protection is more likely to reside in sotagliflozin, solid forms, manufacturing processes, and therapeutic-use patents.
• FDA approval occurred on May 26, 2023, with expected NCE exclusivity extending to approximately May 26, 2028.
• Generic developers could pursue conventional ANDA products, alternative excipient systems, or label-carve-out strategies.
• The most attractive lifecycle opportunities are fixed-dose combinations, dissolution-optimized tablets, and adherence-oriented dosage forms.
• INPEFA faces strong commercial competition from Jardiance and Farxiga.
• Biosimilar risk does not apply because sotagliflozin is a small molecule.
• Commercial success will depend more on clinical positioning, reimbursement, and licensing than on excipient differentiation.

FAQs about INPEFA formulation and commercial strategy

Can a generic manufacturer use different excipients from INPEFA?

Yes. A generic applicant generally may use different inactive ingredients if the formulation meets FDA requirements for safety, quality, dissolution, stability, and bioequivalence.

Is INPEFA an extended-release or delayed-release product?

No. INPEFA is supplied as an immediate-release oral tablet.

Does INPEFA have a biosimilar pathway?

No. Sotagliflozin is a chemically synthesized small molecule and would be approved through the ANDA or another small-molecule pathway, not through the biosimilar framework.

Could an excipient supplier obtain a patent around sotagliflozin tablets?

Potentially, but a patent would need to claim a novel and non-obvious formulation, process, stability improvement, or performance characteristic. The use of standard excipients alone would generally provide limited patent strength.

What is the most valuable lifecycle strategy for INPEFA?

A fixed-dose combination or a clinically differentiated dosage form is likely to offer greater commercial value than a simple excipient substitution. The strategy must improve adherence, tolerability, dosing convenience, or access to a defined patient population.

References

1. Lexicon Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2023). INPEFA (sotagliflozin) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and generic drug approval requirements. FDA.